Biogen (BIIB) Goodwill & Intangibles (2009 - 2026)
Biogen (BIIB) recorded quarterly Goodwill & Intangibles of $15.5 billion in Q1 2026, down 0.81% quarter-over-quarter from $15.7 billion in Q4 2025, and down 3.23% on a YoY basis from $16.1 billion in Q1 2025.
Biogen (BIIB) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Biogen's Goodwill & Intangibles history runs 18 years deep, the most recent figure standing at $15.5 billion for Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 3.23% year-over-year to $15.5 billion; the TTM figure through Mar 2026 stood at $15.5 billion (down 3.23% YoY), while the FY2025 annual figure was $15.7 billion, down 3.1% from the prior year.
- Goodwill & Intangibles was $15.5 billion for Q1 2026 at Biogen, down from $15.7 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $16.3 billion in Q3 2024 to a low of $6.9 billion in Q3 2023.
- Historically, Goodwill & Intangibles has averaged $12.2 billion across 5 years, with a median of $14.5 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles dropped 10.87% in 2023, then surged 135.85% in 2024.
- A 5-year view of Goodwill & Intangibles shows it stood at $7.6 billion in 2022, then soared by 91.89% to $14.6 billion in 2023, then climbed by 10.89% to $16.2 billion in 2024, then decreased by 3.1% to $15.7 billion in 2025, then declined by 0.81% to $15.5 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $15.5 billion (Q1 2026), $15.7 billion (Q4 2025), and $15.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.54 Bn |
| Dec 31, 2025 | 15.67 Bn |
| Sep 30, 2025 | 15.82 Bn |
| Jun 30, 2025 | 15.96 Bn |
| Mar 31, 2025 | 16.06 Bn |
| Dec 31, 2024 | 16.17 Bn |
| Sep 30, 2024 | 16.29 Bn |
| Jun 30, 2024 | 14.46 Bn |
| Mar 31, 2024 | 14.51 Bn |
| Dec 31, 2023 | 14.58 Bn |
| Sep 30, 2023 | 6.91 Bn |
| Jun 30, 2023 | 7.53 Bn |
| Mar 31, 2023 | 7.57 Bn |
| Dec 31, 2022 | 7.60 Bn |
| Sep 30, 2022 | 7.75 Bn |
| Jun 30, 2022 | 7.82 Bn |
| Mar 31, 2022 | 7.91 Bn |
| Dec 31, 2021 | 7.98 Bn |
| Sep 30, 2021 | 8.05 Bn |
| Jun 30, 2021 | 8.15 Bn |